China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999

Watchlist Manager
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Logo
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
Watchlist
Price: 45.69 CNY -3.75% Market Closed
Market Cap: 58.3B CNY
Have any thoughts about
China Resources Sanjiu Medical & Pharmaceutical Co Ltd?
Write Note

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
Total Current Liabilities
ÂĄ12.6B
CAGR 3-Years
22%
CAGR 5-Years
18%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Liabilities
ÂĄ6.9B
CAGR 3-Years
37%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Liabilities
ÂĄ2.5B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
27%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Liabilities
ÂĄ4.8B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Liabilities
ÂĄ13.8B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Liabilities
ÂĄ1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Glance View

Market Cap
58.7B CNY
Industry
Pharmaceuticals

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a leading player in the healthcare sector, has carved a distinguished path through its commitment to innovation and quality. Established in 1992, the company has grown into a comprehensive healthcare provider with a diverse product portfolio that includes traditional Chinese medicine, over-the-counter drugs, and prescription medications. Leveraging its strong distribution network and extensive research and development capabilities, Sanjiu has positioned itself as a trusted brand among consumers and healthcare professionals alike. As the Chinese healthcare market continues to expand, fueled by a growing middle class and increasing health awareness, Sanjiu is well-poised to capitalize on these trends, driving both revenue growth and market share expansion. An investor looking into China Resources Sanjiu will find a company that not only maintains a robust financial foundation but also demonstrates an unwavering focus on sustainable practices and innovation. The company’s strategic partnerships and investments in modern technology, including digital health and telemedicine, further amplify its competitive edge. With a proactive approach to meeting evolving healthcare demands and an eye on regulatory developments, Sanjiu is not just a health-focused enterprise but a forward-thinking entity that embraces change in a dynamic industry. By combining traditional wisdom with modern methodologies, China Resources Sanjiu stands at the intersection of heritage and innovation, offering promising avenues for long-term growth and investor confidence.

Intrinsic Value
57.27 CNY
Undervaluation 20%
Intrinsic Value
Price

See Also

What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
12.6B CNY

Based on the financial report for Jun 30, 2024, China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Total Current Liabilities amounts to 12.6B CNY.

What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
17%

Over the last year, the Total Current Liabilities growth was -1%. The average annual Total Current Liabilities growth rates for China Resources Sanjiu Medical & Pharmaceutical Co Ltd have been 22% over the past three years , 18% over the past five years , and 17% over the past ten years .

Back to Top